Clinical Trial

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-02; most recent amendment 2026-05-27.
Trial Details
NCT Number NCT07445074
Lead Sponsor University of Central Florida
Collaborators: American Epilepsy Society, Orlando Regional Medical Center, Orlando Health Arnold Palmer Hospital
Conditions Epilepsy, Seizure
Enrollment 200 participants
Start Date 2026-05
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-29